Department of Pathology, Erasmus MC, Rotterdam, The Netherlands.
PAL Laboratory, Dordrecht, The Netherlands.
Histopathology. 2020 Nov;77(5):734-741. doi: 10.1111/his.14167. Epub 2020 Sep 24.
Thymic tumours are rare in routine pathology practice. Although the World Health Organization (WHO) classification describes a number of well-defined categories, the classification remains challenging. The aim of this study was to investigate the reproducibility of the WHO classification among a large group of international pathologists with expertise in thymic pathology and by using whole slide imaging to facilitate rapid diagnostic turnover.
Three hundred and five tumours, consisting of 90 biopsies and 215 resection specimens, were reviewed with a panel-based virtual microscopy approach by a group of 13 pathologists with expertise in thymic tumours over a period of 6 years. The specimens were classified according to the WHO 2015 classification. The data were subjected to statistical analysis, and interobserver concordance (Fleiss kappa) was calculated. All cases were diagnosed within a time frame of 2 weeks. The overall level of agreement was substantial (κ = 0.6762), and differed slightly between resection specimens (κ = 0.7281) and biopsies (κ = 0.5955). When analysis was limited to thymomas only, and they were grouped according to the European Society for Medical Oncology Clinical Practice Guidelines into B2, B3 versus A, AB, B1 and B3 versus A, AB, B1, B2, the level of agreement decreased slightly (κ = 0.5506 and κ = 0.4929, respectively). Difficulties arose in distinguishing thymoma from thymic carcinoma. Within the thymoma subgroup, difficulties in distinction were seen within the B group.
Agreement in diagnosing thymic lesions is substantial when they are assessed by pathologists with experience of these rare tumours. Digital pathology decreases the turnaround time and facilitates access to what is essentially a multinational resource. This platform provides a template for dealing with rare tumours for which expertise is sparse.
胸腺肿瘤在常规病理实践中较为罕见。尽管世界卫生组织(WHO)分类描述了许多明确的类别,但分类仍然具有挑战性。本研究的目的是调查一组具有丰富胸腺瘤病理经验的国际病理学家在使用全切片成像技术促进快速诊断周转的情况下,对 WHO 分类的可重复性。
使用基于小组的虚拟显微镜方法,由 13 名具有胸腺瘤专业知识的病理学家,在 6 年的时间内,对 305 例肿瘤(包括 90 例活检和 215 例切除标本)进行了回顾性研究。这些标本根据 WHO 2015 分类进行了分类。对数据进行了统计分析,并计算了观察者间的一致性(Fleiss kappa)。所有病例均在 2 周内得到诊断。总体一致性水平较高(κ=0.6762),切除标本(κ=0.7281)和活检标本(κ=0.5955)之间略有差异。当仅分析胸腺瘤,并根据欧洲肿瘤内科学会临床实践指南将其分为 B2、B3 与 A、AB、B1 和 B3 与 A、AB、B1、B2 时,一致性水平略有下降(κ=0.5506 和 κ=0.4929)。在鉴别胸腺瘤与胸腺癌时存在困难。在胸腺瘤亚组中,B 组存在鉴别困难。
当具有这些罕见肿瘤经验的病理学家对胸内病变进行评估时,诊断的一致性是很高的。数字病理学减少了周转时间,并便于访问基本上是跨国资源。该平台为处理专家资源稀少的罕见肿瘤提供了模板。